Phase 1 Clinical Trial Of PV-10 In Recurrent Breast Cancer Complete, Says Provectus P
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that it has successfully completed its Phase 1 clinical trial of PV-10 in the treatment of recurrent breast carcinoma. Craig Dees, CEO of Provectus, noted, "We are very pleased with the results of this Phase 1 clinical trial, a classic ascending dose study. Its goals were to determine the safety of the treatment and the appropriate dosage.
More... |
All times are GMT -7. The time now is 07:12 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021